PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults
PARC:一项 I/II 期研究,旨在评估聚乙二醇化重组人精氨酸酶 BCT-100 在儿童和青少年复发/难治性癌症中的安全性和活性。
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2024.1296576
Fenwick, Nicola; Weston, Rebekah; Wheatley, Keith; Hodgson, Jodie; Marshall, Lynley; Elliott, Martin; Makin, Guy; Ng, Antony; Brennan, Bernadette; Lowis, Stephen; Adamski, Jenny; Kilday, John Paul; Cox, Rachel; Gattens, Mike; Moore, Andrew; Trahair, Toby; Ronghe, Milind; Campbell, Martin; Campbell, Helen; Williams, Molly W; Kirby, Maria; Van Eijkelenburg, Natasha; Keely, Jennifer; Scarpa, Ugo; Stavrou, Victoria; Fultang, Livingstone; Booth, Sarah; Cheng, Paul; De Santo, Carmela; Mussai, Francis